An anti-platelet-endothelial cell adhesion molecule-1 antibody inhibits leukocyte extravasation from mesenteric microvessels in vivo by blocking the passage through the basement membrane by Wakelin, MW et al.
An Anti-Platelet-Endothelial Cell Adhesion Molecule-1 
Antibody Inhibits Leukocyte Extravasation from Mesenteric 
Microvessels In Vivo by Blocking the Passage through the 
Basement Membrane 
By M.W. Wakelin, M.-J. Sanz, A. Dewar,* S.M. Albelda,~ S.W. Larkin, 
N. Boughton-Smith,~ T.J.Williams, and S. Nourshargh 
From the Applied Pharmacology Department, National Heart and Lung Institute, Imperial College of 
Medicine, Science and Technology, London SW3 6LY; *Electron Microscopy Unit, Royal Brompton 
National Heart & Lung Hospital, London SW3 6NP, United Kingdom; the *Department 
of Medicine, University of Pennsylvania, Pennsylvania 19104-4283; and the ~ Department of
Pharmacology, Astra Charnwood, Loughborough, Leicester LE11 ORI-t, United Kingdom 
Summary 
Platelet-endothelial cell adhesion molecule-1 (PECAM-1, CD31) plays an active role in the 
process of leukocyte migration through cultured endothelial cells in vitro and anti-PECAM-1 
antibodies (Abs) inhibit accumulation ofleukocytes into sites of inflammation i vivo. Despite 
the latter, it is still not clear at which stage of leukocyte migration in vivo PECAM-1 is in- 
volved. To address this point directly, we studied the effect of an anti-PECAM-1 Ab, recog- 
nizing rat PECAM-1, on leukocyte responses within rat mesenteric microvessels u ing intravital 
microscopy. In mesenteric preparations activated by interleukin (IL)-113, the anti-PECAM-1 
Ab had no significant effect on the rolling or adhesion ofleukocytes, but inhibited their migra- 
tion into the surrounding extravascular tissue in a dose-dependent manner. Although in some 
vessel segments these leukocytes had come to a halt within the vascular lumen, often the leuko- 
cytes appeared to be trapped within the vessel wall. Analysis of these sections by electron mi- 
croscopy revealed that the leukocytes had passed through endothelial cell junctions but not the 
basement membrane. In contrast to the effect of the Ab in mesenteric preparations treated with 
IL-113, leukocyte extravasation i duced by topical or intraperitoneal dministration of the 
chemotactic peptide formyl-methionyl-leucyl-phenylalanine was not inhibited by the anti- 
PECAM-1 Ab. These results directly demonstrate a role for PECAM-1 in leukocyte xtravasa- 
tion in vivo and indicate that this involvement is selective for leukocyte xtravasation elicited 
by certain inflammatory mediators. Further, our findings provide the first in vivo indication 
that PECAM-1 may have an important role in triggering the passage of leukocytes through the 
perivascular basement membrane. 
T he migration ofleukocytes from the microvasculature into the tissue is an essential part of an inflammatory 
reaction. This response is mediated by the adhesive interac- 
tion of leukocytes with venular endothelial cells and ap- 
pears to involve multiple sequential steps (1). The initial in- 
teraction appears to be that of a weak reversible adhesion 
between leukocytes and endothelial cells resulting in the 
rolling of leukocytes along the venular wall. There is now 
much in vitro and in vivo evidence demonstrating the im- 
portance of the selectin family of adhesion molecules in this 
phase of the response (2), although more recently, mem- 
bers of the integrin family have also been implicated in the 
phenomenon of leukocyte roiling (3-5). Rolling cells can 
then become activated by chemotactic stimuli expressed/ 
bound on the surface of endothelial cells or in solution at 
the site of inflammation. The interaction of activated leu- 
kocyte adhesion molecules, primarily members of the [31 
and [32 integrins, with their endothelial cell ligands, such as 
intercellular adhesion molecule-1 (ICAM-1) 1 ICAM-2, or 
vascular cell adhesion molecule-1 (VCAM-1) enables roll- 
ing leukocytes to establish a firm adhesive bond with the 
vascular endothelium. Interestingly, the firm attachment of 
leukocytes to venular endothelial cells itself appears to trig- 
1Abbreviations used in this paper: ICAM-1, intercellular dhesion molecule-i; 
PAF, platelet-activating factor; PECAM-1, platelet-endothelial cell adhe- 
sion molecule-i; VCAM-1, vascular cell adhesion molecule-l. 
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ger a secondary activation event within the leukocytes (6), 
and perhaps the endothelial cells, that may mediate the flat- 
tening of  the leukocytes over the endothelium, enabling 
them to locate and penetrate interendothelial cell junctions. 
Despite the increasing number of  in vivo studies investigat- 
ing the molecular interactions involved in the rolling and 
firm adhesion ofleukocytes, there is much less information 
regarding the in vivo mechanisms mediating the passage of  
leukocytes across the vessel wall. 
Platelet-endothelial cell adhesion molecule-1 (PECAM-1), 
a member of the Ig superfamily, is a 130-kD glycoprotein 
expressed on the cell surface of  platelets, leukocytes, and 
endothelial cells. The expression of  PECAM-1 on cultured 
endothelial cells is concentrated at cell-cell junctions (7, 8), 
and there is now strong evidence demonstrating a role for 
this molecule in the passage of  neutrophils and rnonocytes 
across resting and cytokine-activated ndothelial monolay- 
ers in vitro (9). In three different in vivo models of  acute 
inflammation, neutrophil accumulation i to inflamed peri- 
toneum of rats, neutrophil accumulation i to airways after 
local deposition of  IgG immune complexes in rat lungs, 
and neutrophil accumulation i duced by intradermal TNF-cl  
into human skin grafts transplanted onto immunodeficient 
mice, Vaporciyan et al. (10) found that an ant i -PECAM-1 
Ab inhibited the emigration of  neutrophils. Similarly, an 
anti-routine PECAM-1 antibody inhibited thioglycollate- 
induced leukocyte accumulation into mouse peritoneum 
(11). Despite these findings, the precise role of  PECAM-1 
in leukocyte recruitment in vivo is still not fully under- 
stood. The aim of  the present study was to investigate di- 
rectly by intravital and electron microscopy the stage of  
leukocyte emigration at which PECAM-1 was involved, 
and thus determine more precisely the role of  PECAM-1 
in leukocyte xtravasation i  vivo. 
Materials and Methods 
Animals. Male Spragne-Dawley rats (250-300 g) were pur- 
chased from Harlan-Olac (Bicester, Oxfordshire, UK). 
Materials. Pentobarbitone sodium (Sagatal, 60 mg/ml) was 
purchased from Rhone Merieux Ltd. (Harlow, Essex, UK). Hyp- 
norm (0.315 mg/ml fentanyl citrate and 10 mg/ml fluanisone) 
was from Janssen Pharmaceutical Ltd. (Grove, UK). FMLP and 
rabbit IgG, purified from normal serum, were from Sigma 
Chemical Co. (Poole, Dorset, UK). Recombinant rat IL-113 was 
a gift from Dr. K. Vosbeck (Ciba-Geigy Ltd., Basel, Switzerland). 
The anti-PECAM-I antibody was a rabbit polyclonal antibody 
generated by immunization with purified human PECAM-1. 
This Ab cross-reacts with rat PECAM-1 as previously described 
(10). Purified Ab from the preimmune serum was used as con- 
trol Ab in some experiments. Both antibodies were prepared by 
protein G-Sepharose chromatography. A murine anti-rat MHC 
class I mAb from Harlan Sera-Lab (Crawley Down, Sussex, UK) 
was used as a second control antibody. All antibodies were as- 
sayed for endotoxin levels using a Limulus Amebocyte Lysate 
[QCL 1000] kit, from BioWhittaker Inc. (Walkersville, MD). 
The antibodies used in the study had endotoxin levels of <3.5 
ng/ml. This meant hat the rats were injected with <0.8 ng of 
endotoxin. Rats injected with the anti-PECAM-1 Ab were in- 
jected with <0.2 ng of endotoxin and the rats injected with the 
purified rabbit IgG were injected with <0.8 ng of endotoxin. 
Intravital Microscopy. Animals were prepared for intravital mi- 
croscopy as previously described (12). Briefly, rats were sedated 
with an intramuscular injection of Hypnorm (0.2 ml/rat) and in- 
jected intraperitoneally with either 5 ml of sterile saline, 5 ml of 
sterile saline containing 10 ng IL-113, or 5 ml of sterile saline con- 
taining 220 ng of FMLP. Animals were pretreated, 15 min before 
IL-113 or FMLP administration, with either anti-PECAM-1 anti- 
body (1 or 5 mg/kg), control rabbit IgG (in some experiments, 
purified from preimmune serum), or an anti-MHC class I mAb, 
injected via a lateral tail vein. 3.5 h later, the rats were resedated 
intramuscularly with Hypnorm (0.1 rnl) and anesthetized intrave- 
nously with Sagatal (20 mg/kg). Anesthesia was maintained intra- 
venously with 20 mg/kg/h of Sagatal. Animals were then placed 
on a heated stage (37~ and a 1-2-cm midline abdominal inci- 
sion was made to expose the small intestine. A segment of the in- 
testine was carefully exteriorized and placed over a transparent 
circular plastic mount and pinned in place. The exposed tissue 
was continuously superfused with sterile Tyrode solution main- 
tained at 37~ and gassed with 5% CO2 in air. The whole prepa- 
ration was mounted onto the stage of a Diaplan microscope 
(Leitz, Germany) and the mesenteric microcirculation was viewed 
using high magnification water-dipping objectives. A camera 
(model WV CL702 CCD; Panasonic), mounted on the micro- 
scope relayed the image onto a color monitor (Sony Trinitron) 
and the images were recorded using an S-VHS video cassette re- 
corder (model HP,-54700EK; JVC) and a color video printer 
(model CVP-M3E, Sony). To determine the effect of the anti- 
bodies on circulating leukocyte numbers, blood samples were 
taken from the rats before and 4 h after antibody treatment. 
In each animal, leukocyte responses were measured in three to 
five randomly selected postcapillary venules ranging between 20 
and 35 txm in diameter and of at least 400 p~m in length. In each 
vessel, three parameters were measured: leukocyte rolling, adhe- 
sion, and extravasation, as previously described (12). Rolling leu- 
kocytes were defined as cells visibly moving along the endothe- 
lium. For each vessel, the number of rolling cells per minute 
passing a reference point was counted over a 4-rain time period. 
Adherent leukocytes were defined as cells that remained station- 
ary within the vascular lumen for a period of at least 30 s. Adher- 
ent cells were counted in at least four consecutive 100-btm vessel 
segments for every vessel. Leukocyte migration from the micro- 
circulation into the tissue was quantified by counting the number 
of cells that had emigrated out of the vessel up to 50, 50-100, and 
100-150 ~zm away from the vessel wall in parallel with 100-lzm 
vessel segments. At least four readings were taken for each vessel 
at different distances from the vessel wall. 
In a second series of experiments designed to investigate the 
effect of the anti-PECAM-1 Ab on rapid leukocyte responses 
elicited by topical FMLP, rats were prepared for intravital micros- 
copy as described above; basal readings of rolling, adhesion, and 
extravasation were recorded for a period of 15 rain in one venule 
of 20-35 p~m in diameter. The anti-PECAM-1 antibody or a 
control antibody, both at 5 rng/kg, was then administered intra- 
venously; readings of the three leukocyte responses were taken 
for a further 15-rain period. The exteriorized mesentery was then 
superfused with FMLP (final concentration f 10 -7 M, in Tyrode 
solution maintained at 37~ for up to 30 rain and measurements 
of leukocyte rolling, adhesion, and extravasation were taken at 
different time points throughout the duration of the experiment. 
Preparation of Mesenteric Tissues for Electron Microscopy. At the end 
of intravital microscopy studies, the animal was killed by a lethal 
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Figure 1. Effect of anti-PECAM-1 Ab on 
IL-l~-induced leukocyte responses within rat 
mesenteric microvessels, kats were treated in- 
traperitoneally with saline (U]) or 10 ng IL-1[3 
( I ) .  In further groups of animals, rats were 
treated with a control Ab (rabbit IgG, 5 mg/kg 
i.v., []) or the anti-PECAM-1 Ab (1 or 5 nag/ 
kg i.v., k~), 15 min before the i.p. administra- 
tion of IL-113. 4 h later, the mesenteric tissue 
was exteriorized and the responses of leukocyte 
rolling (A), adhesion (B), and extravasation (C) 
quantified. Results are mean + SEM for n = 5 
animals. A significant difference between saline- 
and IL-113- or IL-113 + control Ab-treated 
animals is shown by (*)P <0.05. A significant 
difference between IL-I~ + control Ab and 
IL-I~ + anti-PECAM-1 Ab is shown by 
(+)P <0.01. 
overdose of  sodium pentobarbi tone and the exteriorized mesen-  
tery superfused with 2.5% glutaraldehyde (in 0.05 M sodium ca- 
codylate buffer, pH 7.2) for 10 min. The  area containing the ves- 
sels of  interest was then removed and further fixed in 2.5% 
glutaraldehyde overnight. After washing in cacodylate buffer, the 
mesenteric section was postfixed in 1% osmium tetroxide for 1 h, 
dehydrated in a series of  solutions with increasing methanol  con-  
centrations in water, and transferred to propylene oxide, after which 
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the section was embedded horizontally in araldite. Smaller blocks 
containing the vessels of interest were cut out and mounted verti- 
cally for sectioning. Sections f vessels (1-lxm-thick) were stained 
with alkaline toluidine blue and viewed by light microscopy. For 
electron microscopy, ultrathin sections were stained with uranyl 
acetate and lead citrate. Mesenteric sections from control Ab- and 
anti-PECAM-l-treated animals were prepared for electron mi- 
croscopy in parallel. 
Statistics. Data are expressed as the mean --- SEM for n ani- 
mals and analyzed using the Mann-Whitney nonparametric test, 
or Student's t test when appropriate, for the comparison of two 
samples. P values of <0.05 were considered statistically significant. 
Results 
Effect of Anti-PECAM-1 Ab on Leukocyte Responses in IL- 
l,if-activated Microvessels. In rats injected intraperitoneally 
with saline, there was a basal level of  leukocyte rolling, 
ranging between 16 and 34 leukocytes per minute (25 + 
3.0, mean + SEM, n = 5), a low level of  leukocyte adhe- 
sion within the venules and a small number of  emigrated 
leukocytes in the extravascular tissue (Fig. 1 and Fig. 2 A). 
In animals treated with IL-113 (10 ng i.p. for 4 h), all three 
leukocyte responses measured were significantly increased 
(P <0.05, n = 5), with leukocyte rolling increasing to a 
range between 37 and 57 leukocytes per minute (Fig. 1 and 
Fig. 2 B). IL-113 increased the number of  cells that had em- 
igrated into the surrounding tissue at all three measurement 
points studied (Fig. 3). 
Pretreatment of rats with control antibody (purified rab- 
bit IgG, 5 mg/kg  i.v.), had no significant effect on leuko- 
cyte responses in mesenteric preparations treated with IL-113 
(n = 5, Fig. 1). Similarly, in two rats pretreated with anti- 
body purified from preimmune serum (5 mg/kg i.v.), leu- 
kocyte responses ehcited by IL-113 were not different from 
those obtained in untreated rats (data not shown). In con- 
trast, anti-PECAM-1 Ab (1 or 5 mg/kg i.v.) had no signifi- 
cant effect on the leukocyte responses of rolling and adhesion, 
but dose dependently inhibited the number of  leukocytes 
that had migrated into the tissue (0--50 txm from the venules) 
as compared with rats treated with IL-113 or IL-113 plus con- 
trol Ab (39 and 72% inhibition at 1 and 5 mg/kg, respec- 
tively, Fig. 1 and Fig. 2 C). The leukocyte xtravasation de- 
tected in mesenteric preparations activated with IL-113 in 
Figure 2. Video photomicrographs of the effect ofthe anti-PECAM-1 
Ab on IL-l[3-induced leukocyte extravasation across rat mesenteric mi- 
crovessels. (A) Responses in an animal treated intraperitoneally with sa- 
line; (B) responses in an animal pretreated with control Ab (rabbit IgG, 
5 mg/kg i.v.) before administration of IL-l[3 (10 ng i.p.), clearly showing 
a large number ofleukocytes bo h intravascular and extravascular; and (C) 
responses in an animal pretreated with anti-PECAM-1 Ab (5 mg/kg i.v.) 
before the administration of IL-l[3 (10 ng i.p.) where a layer ofleukocytes 
can be seer~ along the length of the vessel wall. Scale b r,50 Ixm. 
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Figure 3. Effect of anti-PECAM-1 
Ab on leukocyte xtravasation i duced 
by IL-113. Animals were treated with 
control Ab (rabbit IgG, 5 mg/kg i.v.) or 
anti-PECAM-1 Ab (1 or 5 mg/kg i.v.) 
15 min before the intraperitoneal d- 
ministration of IL-113.4 h later, the me- 
senteric tissue was exteriorized and leu- 
kocyte extravasation, at distances of 
0-50, 50-100, and 100-150 Ixm away 
from the vessel wall, across 100-1xm ves- 
sel segments, quantified. Results are 
mean + SEM for n = 5 animals. A sig- 
nificant difference between IL-113 + 
control Ab and IL-113 + anti-PECAM- 
1 Ab is shown by (*)P <0.05. 
anti-PECAM-1 Ab (5 mg/kg)-treated rats was not statisti- 
cally different from the small level of  extravasation detected 
in rats injected intraperitoneally with saline. Further, the 
inhibitory effect of the anti-PECAM-1 Ab (5 mg/kg  i.v.) 
on leukocyte extravasation was evident at all measurement 
points from the vessel wall (Fig. 3). An anti-rat MHC class 
I mAb, binding to both leukocytes and endothelial cells, 
had no effect on the leukocyte extravasation i duced by 
IL-113, i.e., the leukocyte xtravasation responses were 8.2 + 
0.8 (n = 5 rats) and 7.2 + 0.4 (n = 3 rats) for rats treated 
with IL-113 or IL-I[~ plus ant i -MHC class I mAb (5 mg/kg 
i.v.), respectively. There was no significant difference be- 
tween the circulating leukocyte numbers in animals pre- 
treated with the control Abs or the anti-PECAM-1 Ab 
(data not shown). 
In rats treated with the anti-PECAM-1 Ab, very fre- 
quently a layer of leukocytes was observed adjacent o the 
vessel wall (Fig. 2 C). Many of these leukocytes did not ap- 
pear to be within the vascular lumen but appeared to have 
migrated out of the vessel, possibly coming to a halt within 
the vessel wall. These leukocytes could not be counted ac- 
curately. Further, it is important to note that these cells 
were not counted as adherent or extravasated, these param- 
eters being limited to cells that were clearly intravascular or 
extravascular, espectively. Electron microscopy was used 
to localize these leukocytes. 
Investigation of IL-1[3-activated Mesenteric Tissues by Elec- 
tron Microscopy. In control Ab-treated rats (5 mg/kg i.v.), 
in venules within sections taken from IL-l[3-activated me- 
senteric tissues, leukocytes could be seen at different stages 
of their emigration from the vascular lumen to the ex- 
travascular tissue (Fig. 4 A). In addition to leukocytes ap- 
parently adherent o the luminal side of the endothelium, 
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the sections showed leukocytes that had crossed the endo- 
thelial cell layer to the abluminal side. These leukocytes 
had a rounded morphology and appeared to be in the pro- 
cess of migrating through the basement membrane. Elec- 
tron micrographs of sections from IL-l[~-activated mesen- 
teric tissue, from rats pretreated with the anti-PECAM-1 
Ab (5 mg/kg i.v.), also showed leukocytes that appeared to 
be in close contact with the luminal side of the endothe- 
lium (Fig. 4 B). However, in contrast o the sections from 
animals treated with the control Ab, there was a striking 
accumulation of leukocytes between the endothelium and 
the perivascular basement membrane (Fig. 4 B). The en- 
trapment of leukocytes between the endothelium and the 
perivascular basement membrane is very clearly seen in Fig. 
4 C. In 12 random vessel sections prepared from three con- 
trol Ab (rabbit IgG)-pretreated rats (where a total of  439 
leukocytes were counted), of  the 270 leukocytes that had 
passed the endothelial cell junctions, 29.1 --- 7.1% were 
clearly sandwiched between the endothelium and the base- 
ment membrane. In contrast, in 15 vessel sections from 
four anti-PECAM-1 Ab-pretreated rats (where a total of 
490 leukocytes were counted in all the sections), of  the 377 
leukocytes that had crossed the endothelial cell junctions, 
57.5 + 3.3% (P <0.05) were between the endothehum 
and the basement membrane (Fig. 5). These leukocytes, 
the majority of which had an elongated morphology, did 
not appear to be crossing the basement membrane so that 
in some instances they appeared in multiple layers within 
the vessel wall (Fig. 4/3). In these sections, very few leuko- 
cytes were seen in the extravascular tissue as compared with 
sections from control Ab-treated rats. 
Effect of Anti-PECAM-1 Ab on Leukocyte Extravasation I - 
duced by FMLP. As we have previously reported (12), in 
Figure 4, Electron micrographs and corresponding drawings ofmesenteric venules from rats treated with (A, A ') control Ab (rabbit lgG, 5 mg/kg i.v.) 
plus IL-113 (10 ng i.p.) and (B, B') anti-PECAM-1 Ab (5 mg/kg i.v.) plus IL-113 (10 ng i.p.). (C) Part of B at a higher magnification. In the section 
shown in A, leukocytes can be seen at different stages of emigration from the vascular lumen to the extravascular tissue, whereas in the section shown in 
B (more clearly seen in C, C')  there is a marked accumulation ofleukocytes between the endothehum and the basement membrane. The drawings iden- 
tify the vascular lumen (//), intravascular leukocytes (La), leukocytes between the endothehum and the basement membrane (Lb), a leukocyte crossing the 
basement membrane (Lc), extravascular leukocytes (Ld), leukocyte nuclei (Ln), the endothehal cell barrier (E), an endothelial cell nucleus (En), perivascu- 
lar basement membrane (BM), a pericyte (/3, and the mesothelium (M). (A) • (B) • and (C) • 10,500. 
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Figure 5. The effect of the anti-PECAM-1 Ab on the percentage of 
leukocytes trapped between venular endothelial cells and the perivascular 
basement membrane in IL-113-treated mesenteric tissues, as determined 
by electron microscopy. Rats were treated with a control Ab (rabbit IgG, 
animals treated intraperitoneally withchemotactic peptide 
FMLP (220 ng for 4 h), the leukocyte responses of adhesion 
and ext ravasat ion  were  greater  than  the  levels detected  in  
rats t reated in t raper i tonea l ly  w i th  sal ine (results not  shown) .  
P re t reatment  o f  rats w i th  a cont ro l  ant ibody  (pur i f ied rabb i t  
IgG,  5 mg/kg  i.v.) or  the ant i -PECAM-1  Ab  (5 mg/kg  i.v.) 
had  no  effect on  the  FMLP- induced leukocyte  adhes ion  
(data not  shown) ,  or  more  impor tant ly ,  FMLP- induced 
leukocyte  ext ravasat ion  (Fig. 6). 
5 mg/kg i.v., open column) or the anti-PECAM-1 Ab (5 mg/kg i.v., closed 
column) 15 rain before the i.p. administration of IL-1 ~. 4 h later, the me- 
senteric tissue was exteriorized and tissue sections prepared for electron 
microscopy. The graph represents he number ofleukocytes observed be- 
tween the venular endothelium and the perivascular basement membrane, 
quantified as the percentage of the total number of leukocytes that had 
passed the endothelial cell junctions. The results are from 12-15 sections 
prepared from n = 3-4 rats within each group. A significant difference is 
shown by (*)P <0.05. 
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Effect of the anti-PECAM-1 Ab on leukocyte xtravasation 
induced by i.p. FMLP. Rats were treated with saline (i.p., open column), a
control Ab (rabbit IgG, 5 mg/kg i.v.) plus FMLP (220 ng i.p.; dosed col- 
umn), or the anti-PECAM-1 Ab (5 mg/kg i.v.) plus FMLP (220 ng i.p.; 
crosshatched column). 4 h later, the mesenteric tissue was exteriorized and 
leukocyte xtravasation quantified. R.esults are mean -+ SEM for n = 4 
animals. A significant difference between saline- and IL-l[3-treated rats is 
shown by (*)P <0.05. 
To investigate the effect of  the ant i -PECAM-1 Ab on 
rapid responses elicited by FMLP, additional experiments 
were carried out to test the effect of  the antibody on 
changes in leukocyte responses after the topical administra- 
tion of  FMLP. In control rats, whereas topical administra- 
tion of  FMLP (final concentration of  10 -7 M) had no sig- 
nificant effect on the number of  rolling leukocytes (results 
not shown), it did cause a rapid increase in leukocyte adhe- 
sion (556% increase above basal evels at 30 rain, n = 5 rats, 
P <0.05, Fig. 7 A) and leukocyte xtravasation (395% in- 
crease above basal levels at 30 rain, n = 5 rats, P <0.05, 
Fig. 7 B). The responses to topical FMLP were essentially 
complete within 30-45 min (Fig. 7 and data not shown). 
Pretreatment of  rats with a control Ab (5 mg/kg i.v.), 15 
rain before the topical administration of FMLP, had no sig- 
nificant effect on FMLP-induced leukocyte responses (Fig. 7). 
Similarly, the ant i -PECAM-1 Ab (5 mg/kg  i.v.) had no 
significant effect on FMLP- induced leukocyte adhesion, 
and more importantly, had no significant effect on the leu- 
kocyte extravasation i duced by the topical chemotactic 
peptide (Fig. 7). 
Interestingly, in mesenteric preparations activated by IL-113 
in control Ab-treated rats, the topical administration of  
FMLP resulted in a further increase in leukocyte adhesion 
(data not shown) and extravasation above the levels elicited 
by the cytokine (Fig. 8). In animals pretreated with the 
ant i -PECAM-1 Ab, although the leukocyte extravasation 
induced by IL-113 was less than that observed in rats treated 
with the control Ab, the topical administration of  FMLP 
stimulated the leukocytes that had come to a halt at the 
vessel wall to migrate into the extravascular tissue (Figs. 8 
and 9). Thus it would appear that, in the presence of the 
ant i -PECAM-1 Ab, FMLP could induce the migration of  
the arrested leukocytes through the basement membrane. 
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Figure 7. Effect of the anti-PECAM-1 Ab on leukocyte adhesion and 
extravasation induced by topical FMLP. Three groups of animals were 
used: untreated rats ([~), rats treated with a control Ab (rabbit IgG, 5 mg/ 
kg i.v., []), and rats treated with the anti-PECAM-1 Ab (5 mg/kg i.v., 
k~). The animals were treated with the control Ab or the anti-PECAM-1 
Ab and basal readings of leukocyte adhesion (A) and extravasation (B) re- 
corded. 15 min later, FMLP (at a final concentration f10 -7 M) was ap- 
plied topically to the preparation a d readings taken at 15 and 30 n'fin af- 
ter application. Results are mean + SEM for n = 4-5 rats. A significant 
difference between baseline values and FMLP-induced responses is shown 
by (*)P <0.05. 
Discuss ion  
Previous studies have shown that PECAM-1 mediates 
neutrophil and monocyte extravasation through endothe- 
lial cell monolayers in vitro (9) and ant i -PECAM-1 Abs in- 
hibit neutrophil and monocyte accumulation into sites of  
inflammation in vivo (10, 11). Despite the latter studies, 
the stage of  emigration at which ant i -PECAM-1 antibodies 
inhibit leukocyte accumulation and hence the precise role 
of  PECAM-1,  under dynamic conditions in vivo, remain 
unclear. The aim of  the present study was to address this 
point, determining at which stage in the migration of  leu- 
kocytes from the vascular lumen to the extravascular tissue 
PECAM-1 was involved. For this purpose, intravital mi-  
croscopy was used to visualize directly the effect of  an anti- 
body recognizing rat PECAM-1 on leukocyte responses 
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Figure 8. Effect of the anti-PECAM-1 Ab on 
leukocyte xtravasation nduced by FMLP in IL- 
l~-treated rats. ILats were pretreated with control 
Ab (rabbit IgG) or anti-PECAM-1 Ab before i.p. 
IL-113.4 h later, the mesenteric t ssue was exterior- 
ized and leukocyte xtravasadon 30 rain after the 
topical administration of Tyrode (open columns) or 
FMLP (I0-7M; dashed columns) quantified. Re- 
sponses are mean - SEM for n = 3 animals. A sig- 
nificant difference between the leukocyte extrava- 
sation after topical Tyrode and FMLP is shown by 
(*)V <0.05. 
within activated rat mesenteric microvessels in vivo. In ad- 
dition, electron microscopy was used to determine the site 
of the inhibitory effect of the anti-PECAM-1 Ab. This Ab, 
which has been well characterized and shown to function 
as both intact IgG and as Fab fragments, has previously 
been shown to inhibit neutrophil accumulation int  sites of 
acute inflammation i  rat peritoneum and rat lungs, and 
into human skin grafts on immunodeficient mice (10). 
In control rats, the i.p. injection of recombinant rat IL-113, 
4 h before the exteriorization of the mesenteric tissue, in- 
duced an inflammatory esponse that was associated with a 
significant increase in leukocyte rolling and adhesion within 
the mesenteric venules and a large number of emigrated 
leukocytes in the extravascular tissue. Although pretreat- 
ment of rats with an anti-PECAM-1 Ab, but not control 
Abs, had no effect on the IL-113-induced leukocyte re- 
sponses of rolling and adhesion, it significantly inhibited the 
leukocyte xtravasation elicited by the cytokine. The effect 
of the anti-PECAM-1 Ab was dose dependent, resulting in 
39 and 72% inhibition of extravasation at 1 and 5 mg/kg of 
the Ab, respectively. These results, showing a role for PE- 
CAM-1 in IL-113-induced leukocyte xtravasation by di- 
rect observation i vivo, provide a mechanistic explanation 
for the inhibitory effect of anti-PECAM-1 Abs on leuko- 
cyte extravasation into sites of inflammation (10, 11). 
In animals receiving the anti-PECAM-1 Ab, the inhibition 
Figure 9. Video photomicrographs s owing the 
effect of the anti-PECAM-1 Ab on leukocyte ex- 
travasation induced by FMLP in IL-113-treated rats. 
For experimental details, ee legend to Fig. 8. Briefly, 
rats were treated with theanti-PECAM-1 Ab before 
intraperitoneal IL-113 and 4 h later, the mesenteric 
tissue was exteriorized. The photos show responses 
before (A) and 30 min after (/3) the topical adminis- 
tration of FMLP (10 -7 M). Scale bar, 50 Ixm. 
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of leukocyte xtravasation was associated with thickening 
of venular walls, which resembled a "wall of leukocytes" 
lining the length of vessel segments in the live microcircu- 
lation (Fig. 2 C). This finding is similar to the histological 
results ofBogen et al. (11) showing an increase in the num- 
ber of leukocytes lining the length of mesenteric venular 
walls in anti-PECAM-l-treated mice. In the study of Bo- 
gen et al. (11), these leukocytes appeared retained within 
the vessels. In our study, in order to determine the precise 
site at which the leukocytes had come to a halt at the vessel 
wall, we used electron microscopy to analyze mesenteric 
tissues from anti-PECAM-1 Ab-treated rats. To our sur- 
prise, detailed analysis of numerous ections, obtained from 
several rats, indicated that within these animals the leuko- 
cytes had migrated through venular endothelial cell junc- 
tions, but not the perivascular basement membrane, and 
were thus trapped within the vessel wall. These leukocytes 
did not appear to be able to cross the basement membrane, 
resulting in the formation of multiple layers of leukocytes 
between the endothehal cell barrier and the perivascular 
basement membrane in some vessel segments. 
Although early in vitro studies demonstrated a role for 
PECAM-1 in monocyte and neutrophil transendothelial 
cell migration through unstimulated and TNF-oe-stimu- 
lated endothelial ceil monolayers (9), recently, PECAM-1 
has also been implicated in leukocyte interactions with 
components of the basement membrane (13). Liao et al. 
(13) showed that mAbs whose epitopes mapped to Ig do- 
mains 1-2 of the PECAM-1 molecule selectively blocked 
monocyte migration through unstimulated cultured endo- 
thehal ceils in vitro, whereas mAbs recognizing domain 6 of 
the molecule inhibited the penetration of monocytes into 
the underlying collagen gel. Thus, the antibody used in our 
in vivo studies may be predominantly directed against Ig 
domain 6 of PECAM-1. Based on in vitro studies, in addi- 
tion to PECAM-1, a number of other adhesion molecules 
have also been implicated in the process of IL-l-induced 
leukocyte xtravasation (14). Although neutrophil migration 
through IL-l-activated endothehal cell monolayers appears 
to rely heavily on ICAM-1 (15), E-selectin, has also been 
implicated in this response (16). ICAM-1, E-selectin and 
VCAM-1 all appear to have roles in lymphocyte and eosi- 
nophil migration (17, 18). The relative contribution and 
precise role of these molecules in leukocyte xtravasation 
in vivo remains to be determined. In addition to adhesion 
molecules, it is now clear that certain endothelial cell asso- 
ciated chemoattractants, such as platelet-activating factor 
(PAF) and IL-8, are also involved in the passage of neutro- 
phils through IL-l-activated endothelial ceils in vitro (19, 
20). In support of these findings, we have recently shown 
that PAF receptor antagonists can selectively block the ex- 
travasation of leukocytes through IL-l-activated rat me- 
senteric microvessels in vivo (12). These observations can 
also explain the finding that pretreatment of 111In-neutro- 
phils with pertussis toxin to uncouple receptors, in addition 
to inhibiting the accumulation i duced by chemoattrac- 
tants such as FMLP, inhibited the accumulation of 111In- 
neutrophils in response to intradermal IL-1 in rabbits (21). 
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In these experiments, pertussis toxin may have inhibited 
the neutrophil accumulation i duced by IL-1 by uncou- 
pling the leukocyte PAF receptors. Interestingly, whereas 
PAF receptor antagonists and the anti-PECAM-1 Ab both 
inhibited IL-16-induced leukocyte xtravasation, there ap- 
peared to be one important difference in the profile of their 
inhibitory effects. In rats pretreated with PAF receptor an- 
tagonists, the leukocytes appeared to remain within the 
vascular lumen, whereas in animals pretreated with the anti- 
PECAM-1 Ab, the leukocytes appeared trapped in the ves- 
sel wall. 
The in vitro studies ofLiao et al. (13) and our in vivo re- 
sults implicate a functional role for PECAM-1 in the pas- 
sage ofleukocytes through the basement membrane. How- 
ever, the mechanism by which this occurs is unclear. A 
possible xplanation is that an important role of PECAM-1 
in vivo is as a molecule triggering leukocyte activation. It 
may be that the hgation of PECAM-1, via domain 6 of the 
Ig molecule, is involved in the local activation of leuko- 
cytes at endothelial cell junctions, resulting in the stimula- 
tion of other mechanisms that enable the leukocytes to in- 
teract with and penetrate the basement membrane. This 
may involve both adhesive interaction with basement 
membrane components and proteolytic degradation by sur- 
face-expressed nzymes on the leukocytes. Indeed, there is 
now much in vitro evidence indicating that PECAM-1, as 
well as acting as an adhesion molecule, can act as a receptor 
capable of triggering leukocyte activation. In this context, 
PECAM-l-dependent interactions can activate both 61 and 
62 integrins on leukocytes or integrin-expressing COS cells 
(22-25). A PECAM-l-dependent activation of 61 and 62 
integrins may facilitate both the passage of leukocytes 
through endothelial ceil junctions and their interaction with 
basement membrane components. In contrast to the wen- 
established role of 62 integrins in neutrophil migration in 
vivo (1, 14), there is as yet no in vivo evidence for the in- 
volvement of 61 integrins in this response. However, in 
vitro studies have shown that 61 integrins can be induced 
on the surface of transmigrating eutrophils (26), and that 
61 integrins can mediate the interaction of neutrophils with 
components of the basement membrane such as laminin 
(27, 28). In addition to endothelial ceils and extracellular 
matrix proteins, pericytes may also play a role in regulating 
the passage of leukocytes through the vessel wall. In most 
of the tissue sections analyzed by electron microscopy, 
pericytes could be seen in the vessel wall embedded within 
the basement membrane (Fig. 4). Hence, an alternative ex- 
planation of our results is that PECAM-1 may be involved in 
the interaction of leukocytes with microvascular pericytes. 
Although the cascade of intermolecular interactions me- 
diating the passage of leukocytes through IL-l-activated 
endothelial cells is yet to be fully understood, sequential c- 
tivation of leukocytes may be critically important in this 
process. Hughes et al. (29) have presented evidence show- 
ing that increments in chemotactic stimuli are required to 
bring CD11b/CD18 to the surface of neutrophils (from 
granules), and that this newly mobilized CD11b/CD18 is 
necessary for adherence-dependent neutrophil migration. 
This concept ofa stepwise increase in neutrophil activation 
agrees well with our observations indicating roles for both 
PAF and PECAM-1 in leukocyte xtravasation. A possible 
explanation of our findings may involve a sequence of 
events uch as the following: (a) stimulation of endothelial 
cells by IL-1 results in the upregulation or activation ofse- 
lectins and generation of PAF which remains predomi- 
nantly endothelial cell associated; (b) tethering of leuko- 
cytes to the endothelium by selectins allows an interaction 
between the endothelial cell-associated PAF and the leu- 
kocyte's cell surface PAF receptors; (c) stimulation of leu- 
kocytes by PAF triggers a partial activation of leukocyte 132 
integrins timulating the firm adhesion and transendothelial 
cell migration of the leukocytes, a response involving 
ICAM-1, PECAM-1 (domains 1-2), as well as other in- 
duced endothelial cell adhesion molecules; and (d) at the 
endothelial cell junctions, the additional interaction of the 
leukocytes with endothelial cell PECAM-1 (through do- 
main 6) triggers further activation of leukocyte 61 and 132 
integrins and release of granular proteases aiding the passage 
of leukocytes across the perivascular basement membrane. 
Hence, in animals treated with PAF receptor antagonists, 
leukocyte xtravasation may have been blocked by inhibit- 
ing the passage of leukocytes into the interendothelial cell 
junctions, thus forcing the leukocytes to remain within the 
vasculature. In contrast, in animals treated with the anti- 
PECAM-1 Ab (possibly predominantly directed against Ig 
domain 6), once the leukocytes had entered the endothelial 
cell junctions, the Ab may have prevented the PECAM-1- 
dependent activation of leukocyte integrins that mediates 
and indeed propagates the passage of leukocytes across the 
basement membrane, thus maintaining the leukocytes within 
the vessel wall. This proposal is currently under further in- 
vestigation. 
The above proposal is further supported by our find- 
ings that both PAF receptor antagonists (12) and the anti- 
PECAM-1 Ab had no effect on the rapid leukocyte ex- 
travasation induced by the chemotactic peptide FMLP. 
One clear difference between the responses elicited by the 
cytokine and the chemotactic formyl peptide is that pre- 
sumably the extravasation induced by FMLP is as a result of 
direct leukocyte activation and is not dependent on endo- 
thelial cell stimulation. Thus, leukocyte activation via en- 
dothelial cell-associated PAF or PECAM-1 is not required 
for the FMLP-induced leukocyte extravasation. It is im- 
portant o note that FMLP was able to induce the rapid mi- 
gration through the basement membrane of the leukocytes 
held up by anti-PECAM-1 Ab in the IL-lf3-treated me- 
sentery (Fig. 8). These results, which clearly show that in 
the same animal the anti-PECAM-1 Ab inhibits the ex- 
travasation i duced by IL-113 but not FMLP, further dem- 
onstrate that (a) the inhibitory effect of the anti-PECAM-1 
Ab on leukocyte xtravasation was specific to the response 
induced by certain stimuli including IL-113, and (b) the an- 
tibody did not have a nonspecific inhibitory effect on the 
leukocytes. It has also been shown that anti-PECAM-1 Abs 
and soluble PECAM-1 do not affect chemoattractant-induced 
neutrophil or monocyte chemotaxis n vitro (9, 10). Finally, 
in agreement with our previous findings (21), our present 
studies with FMLP and IL-1 also indicated the apparent 
difference in the potency of these stimuli in eliciting neu- 
trophil accumulation i  vivo. Even though FMLP had to 
be used at an ~20-fold-greater dose than IL-113 in order to 
induce leukocyte xtravasation, the level of FMLP-induced 
response was smaller than that observed with the cytokine, 
suggesting that the difference in the profile of effects een 
with the anti-PECAM-1 Ab on the two stimuli is unlikely 
to be due to the difference in their respective doses. 
Full details of the mechanisms mediating the passage of 
leukocytes across venular walls are still unknown. However, 
our results provide the first direct evidence for a role for 
PECAM-1 in leukocyte xtravasation across venules acti- 
vated by IL-113, but not FMLP, in vivo. These findings 
demonstrate a differential requirement for PECAM-1 in the 
recruitment of leukocytes in response to different inflam- 
matory stimuli and strongly implicate PECAM-1 in the pas- 
sage ofleukocytes across the basement membrane in vivo. 
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